PMID- 37969291
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231117
IS  - 2072-1439 (Print)
IS  - 2077-6624 (Electronic)
IS  - 2072-1439 (Linking)
VI  - 15
IP  - 10
DP  - 2023 Oct 31
TI  - Neoadjuvant immunotherapy combined with chemotherapy in the treatment of stage 
      III lung squamous cell carcinoma: a retrospective cohort study.
PG  - 5658-5668
LID - 10.21037/jtd-23-1175 [doi]
AB  - BACKGROUND: Neoadjuvant immunochemotherapy has been proven to be a successful 
      therapeutic strategy for patients with locally advanced non-small cell lung 
      cancer (NSCLC). Nevertheless, there is a paucity of information regarding 
      surgical feasibility and safety as well as tumor response. The present study 
      aimed to investigate the therapeutic and surgical outcomes for patients with 
      stage III lung squamous cell carcinoma (LSCC). METHODS: Patients with stage III 
      potentially resectable LSCC treated with neoadjuvant immunochemotherapy at The 
      First Affiliated Hospital of Ningbo University between March 2020 and June 2022 
      were retrospectively included. Oncologic outcomes and intraoperative and 
      postoperative variables were assessed. RESULTS: A total of 17 locally advanced 
      LSCC patients were included in the study. Patients in stages IIIA and IIIB were 
      represented by 10 (58.8%) and 7 (41.2%) cases, respectively. A minimally invasive 
      procedure was successfully completed in 12 out of 17 cases (70.6%). A total of 10 
      patients (58.8%) had standard lobectomies performed, 1 (5.9%) had a bilobectomy, 
      3 (17.6%) had pneumonectomies, and 1 (5.9%) had a wedge resection. A total of 7 
      patients (41.2%) experienced postoperative complications, and there were no 30- 
      or 90-day mortalities. The 2-year disease-free survival (DFS) and overall 
      survival (OS) rates were 76.6% and 82.5%, respectively. The rate of major 
      pathological response (MPR) was 70.6%. CONCLUSIONS: Lung resection after 
      immunochemotherapy for potentially resectable stage III LSCC is feasible and 
      safe. This treatment strategy results in a significant pathologic response and 
      promising rates of OS at 2 years.
CI  - 2023 Journal of Thoracic Disease. All rights reserved.
FAU - Guo, Jing
AU  - Guo J
AD  - Department of Thoracic Surgery, The First Affiliated Hospital of Ningbo 
      University, Ningbo, China.
FAU - Lin, Shuai-Dong
AU  - Lin SD
AD  - Department of Thoracic Surgery, The First Affiliated Hospital of Ningbo 
      University, Ningbo, China.
FAU - Minervini, Fabrizio
AU  - Minervini F
AD  - Department of Thoracic Surgery, Cantonal Hospital Lucerne, Lucerne, Switzerland.
FAU - Geraci, Travis C
AU  - Geraci TC
AD  - Division of Thoracic Surgery, Department of Cardiothoracic Surgery, New York 
      University Langone Health, New York, NY, USA.
FAU - Kim, Jae Jun
AU  - Kim JJ
AD  - Department of Thoracic and Cardiovascular Surgery, Uijeongbu St. Mary's Hospital, 
      The Catholic University of Korea, College of Medicine, Seoul, Republic of Korea.
FAU - Tong, Chang-Yong
AU  - Tong CY
AD  - Department of Thoracic Surgery, The First Affiliated Hospital of Ningbo 
      University, Ningbo, China.
FAU - Li, Xin-Jian
AU  - Li XJ
AD  - Department of Thoracic Surgery, The First Affiliated Hospital of Ningbo 
      University, Ningbo, China.
FAU - Cao, Chao
AU  - Cao C
AD  - Department of Respiratory and Critical Care Medicine, The First Affiliated 
      Hospital of Ningbo University, Ningbo, China.
LA  - eng
PT  - Journal Article
DEP - 20230912
PL  - China
TA  - J Thorac Dis
JT  - Journal of thoracic disease
JID - 101533916
PMC - PMC10636463
OTO - NOTNLM
OT  - Non-small cell lung cancer (NSCLC)
OT  - immunochemotherapy
OT  - lung squamous cell carcinoma (LSCC)
OT  - neoadjuvant therapy
OT  - survival
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://jtd.amegroups.com/article/view/10.21037/jtd-23-1175/coif). The authors 
      have no conflicts of interest to declare.
EDAT- 2023/11/16 06:45
MHDA- 2023/11/16 06:46
PMCR- 2023/10/31
CRDT- 2023/11/16 04:19
PHST- 2023/07/27 00:00 [received]
PHST- 2023/08/31 00:00 [accepted]
PHST- 2023/11/16 06:46 [medline]
PHST- 2023/11/16 06:45 [pubmed]
PHST- 2023/11/16 04:19 [entrez]
PHST- 2023/10/31 00:00 [pmc-release]
AID - jtd-15-10-5658 [pii]
AID - 10.21037/jtd-23-1175 [doi]
PST - ppublish
SO  - J Thorac Dis. 2023 Oct 31;15(10):5658-5668. doi: 10.21037/jtd-23-1175. Epub 2023 
      Sep 12.